This article discusses clinical data for noncovalent Bruton tyrosine kinase inhibitors (BTKis), novel strategies in CLL, and the practical management of BTKi toxicities.
Luisa Giannangelo, MBA, RPh
Advertisement
Articles by Luisa Giannangelo, MBA, RPh
This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.
Data shed light on brentuximab vedotin plus nivolumab, bendamustine, or gemcitabine.
Integrating immunotherapies will continue to improve patient outcomes and quality of life.
Advertisement
Latest Updated Articles
Recent Clinical Trials Reveal Important Updates in Adjuvant Therapy for Resectable Non–Small Cell Lung CancerPublished: October 20th 2023 | Updated:
Chronic Lymphocytic Leukemia: A Review of Noncovalent BTK Inhibitors, Novel Agents, and Toxicity Management of BTK InhibitorsPublished: August 19th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
In the Fragmented Landscape of Long COVID Care, Pharmacists Are Essential
3
FDA Approves Gazyva for Active Lupus Nephritis
4
Amivantamab Shows 45% Response Rate in Pretreated Head and Neck Cancer: OrigAMI-4 Findings
5
